Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

Psyence BioMed receives ethics approval for psilocybin trial in cancer patients

Psyence BioMed (NASDAQ:PBM) announced that it has received approval from the Bellberry Human Research Ethics Committee to use its psilocybin product, NPX5, in its ongoing Phase IIb clinical trial for adjustment disorder in cancer patients.

Leia mais: Psyence BioMed receives ethics approval for psilocybin trial in cancer patients
Grafa
Health

Altimmune's pemvidutide achieves key milestones in IMPACT Phase 2b trial for MASH

Altimmune (NASDAQ:ALT), a clinical-stage biopharmaceutical company focused on therapies for liver diseases, today announced encouraging topline results from its IMPACT Phase 2b trial of pemvidutide, a dual glucagon/GLP-1 receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Leia mais: Altimmune's pemvidutide achieves key milestones in IMPACT Phase 2b trial for MASH
Grafa
Health

ABL Diagnostics and ProPhase Labs announce non-binding LOI for proposed reverse merger

ABL Diagnostics has announced that its controlling shareholder, Advanced Biological Laboratories S.A., and ProPhase Labs, (NASDAQ:PRPH) have entered into a non-binding letter of intent (LOI) for a proposed reverse merger.

Leia mais: ABL Diagnostics and ProPhase Labs announce non-binding LOI for proposed reverse merger